Journal article
Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
Abstract
GUIDELINE QUESTIONS: 1) What is the role of different schedules or doses of radiotherapy in patients with unresected, clinical or pathological, stage III non-small-cell lung cancer (NSCLC)? 2) Does chemotherapy combined with radiotherapy provide improved survival compared with radiotherapy alone in patients with unresected NSCLC?
OBJECTIVE: To make recommendations about the role of chemotherapy and radiotherapy in the treatment of unresected …
Authors
Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
Journal
Cancer prevention & control : CPC = Prévention & contrôle en cancérologie : PCC, Vol. 1, No. 3, pp. 249–259
Publication Date
August 1997
ISSN
1206-548X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCisplatinConfidence IntervalsDose Fractionation, RadiationHumansLung NeoplasmsMeta-Analysis as TopicNeoplasm StagingOutcome Assessment, Health CareProportional Hazards ModelsQuality of LifeRadiotherapy DosageRandomized Controlled Trials as TopicRisk FactorsSurvival Rate